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Absence of Cutaneous TNFa-Producing CD4þ T Cells
and TNFa may Allow for Fibrosis Rather than
Epithelial Cytotoxicity in Murine Sclerodermatous
Graft-Versus-Host Disease, a Model for Human
Scleroderma
David Askew1, Lixin Zhou1, Cayun Wu1, Guofen Chen1, and Anita C. Gilliam1,2
Graft-versus-host disease (GVHD) is a complication of hematopoietic cell transplantation and is a major source
of morbidity and mortality. Two main forms of GVHD occur: cytotoxic GVHD (Cyt GVHD), in which TNFa is a
critical cytokine in epithelial injury, and sclerodermatous GVHD (Scl GVHD), in which TGFb plays a major role in
fibrosis. To understand the critical early events in GVHD and scleroderma, we are studying a murine model that
uses differences in minor histocompatability antigens to generate Scl GVHD. We asked the question: what is the
immune environment in this model that promotes fibrosis rather than the epithelial injury of Cyt GVHD? We
found that in Scl GVHD, cutaneous CD4þ T cells produced IFNg and IL-2 but not TNFa, also absent by gene array
analysis. The role of cutaneous CD4þ T cells in Scl GVHD may not be an active process through production of
TGFb, but may rather be a passive one due to lack of antigen-presenting cell (APC) support for CD4þ T cells and
failure to produce TNFa, a potent inhibitor of TGFb-induced fibrosis as well as inducer of keratinocyte
apoptosis. These APC–T cell interactions and the cytokine environment promote fibrosis rather than cytotoxic
epithelial injury in skin in Scl GVHD.
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INTRODUCTION
Graft-versus-host disease (GVHD) is the major complication
of hematopoietic cell transplantation with high morbidity and
mortality. There are two major forms of GVHD, acute
cytotoxic or chronic GVHD. Cytotoxic GVHD (Cyt GVHD)
is characterized by epithelial injury. When it progresses to
chronic disease, it is typically a lichenoid or lupus-like
chronic interface dermatitis in skin. A subset of chronic
GVHD is sclerodermatous GVHD (Scl GVHD), which is
scleroderma-like and tends to be more chronic and fibrotic
with minimal epithelial injury. For long-term survivors of
hematopoietic cell transplantation there is a 40–60% chance
of developing chronic GVHD. Occurrence, severity, and
form of GVHD depend on the degree of human leukocyte
antigen mismatch and on the host conditioning [X-ray
therapy and chemotherapy to ablate recipient bone marrow
(BM)] before transplantation. Even when human leukocyte
antigen-identical donor cells are used, minor histocompat-
ability antigen mismatches can still trigger GVHD (Vogelsang
et al., 2003).
Cyt GVHD is thought to occur in three stages, which
consist of a conditioning phase (cytokine storm), donor T-cell
activation phase, and effector phase in which cytotoxic
T cells, natural killer cells, and inflammatory cytokines cause
epithelial cell injury (dermatitis, diarrhea, and hepatitis in
that order) (Ferrara et al., 1996, 1999; Vogelsang et al., 2003).
Tumor necrosis factor (TNF)a has a critical role in Cyt GVHD
as it is released in response to lipopolysaccharide from gut
flora entering the circulation through damaged gastrointesti-
nal epithelium and is part of the ‘‘cytokine storm’’ that can
activate resident antigen-presenting cells (APCs). TNFa is also
part of the effector phase because it can induce apoptosis, a
major manifestation of epithelial injury. Blocking TNFa with
antibodies is effective in steroid-resistant Cyt GVHD (Couriel
et al., 2004).
The fibrosing variant of GHVD, Scl GVHD, makes up
approximately 10–15% of chronic GVHD (Vogelsang et al.,
2003) and is less well understood. Like scleroderma,
individuals with Scl GVHD develop skin and lung fibrosis
and disease is typically refractory to immunosuppressant
treatment. The cytokine environment leading to fibrosis in Scl
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GVHD has not been studied, but TGFb is known to be a
major driver of fibrosis in scleroderma. Well-established
scleroderma is thought to have a Th2-like cutaneous cytokine
environment (Abraham and Varga, 2005).
To understand the mechanisms that initiate Scl GVHD, we
examined early events in a murine Scl GVHD model
generated by transplanting B10.D2 (H-2d) BM and spleen
cells into lethally irradiated Balb/c mice (H-2d). Balb/c mice
transplanted with syngeneic Balb/c BM and spleen cells serve
as controls [control BM transplantation (BMT)]. We have
previously shown that CD11bþ macrophages predominate
over CD3þ T cells in skin in early Scl GVHD. The cutaneous
macrophages express scavenger receptors, suggesting a role
in antigen presentation (McCormick et al., 1999; Zhang et al.,
2003). Messenger RNA (mRNA) for TGFb1 is upregulated by
approximately four- to sixfold by RT-PCR (McCormick et al.,
1999; Zhang et al., 2003) and by gene array analysis (Zhou
et al., 2007) and monocyte/macrophages are the major
producers of TGFb in skin (Zhang et al., 2002a).
Because the earliest initiating events of self-reactivity
would be expected to occur in the spleen in transplanted
animals, we have focused on the APC–T cell interactions and
the cytokine environments in spleen and skin and asked these
questions: (1) what are the major effector T cells and APCs
that activate them in Scl GVHD? (2) What is the immune
environment that leads to TGFb-driven fibrosis rather than
TNFa-driven cytotoxicity?
Here, we demonstrate that CD4þ T cells are activated in
spleen in early murine Scl GVHD, whereas only CD11cþ
dendritic cells (DCs) are activated in the spleen. Activated
CD4þ T cells are found in the skin of normal mice, control
BMT mice, and in Scl GVHD mice, whereas CD11bþ
macrophages and CD11cþ DCs are activated in the skin only
in Scl GVHD mice. Therefore, there are different APC–T cell
interactions in spleen and skin in Scl GVHD mice and the
presence of activated T cells by itself is not sufficient to
activate resident APCs in the skin.
Splenic CD4þ T cells make TNFa, but cutaneous CD4þ T
cells do not, and TNFa mRNA is not present by gene array
analysis, an important finding in explaining the lack of
epithelial cell injury in Scl GVHD. Thus, although splenic
CD11cþ DCs are associated with TNFa production, neither
cutaneous CD11bþ macrophages nor CD11cþ DCs are
associated with TNFa production. Thus, TNFa production by
CD4þ T cells may be dependent on the local APC–T cell
interactions. The failure of CD4þ T cells to make TNFa may
account for the development of Scl GVHD instead of Cyt
GVHD, because TNFa is a potent inhibitor of TGFb-induced
fibrosis as well as a critical factor in keratinocyte apoptosis.
RESULTS
Increased skin thickening and not epithelial or follicular
keratinocyte apoptosis is a hallmark of Scl GVHD
We examined hematoxylin and eosin staining of ear and skin
sections of either normal mice or mice at 21 days post-BMT.
Ear sections from normal mice (not irradiated or transplanted)
and control BMT mice showed little evidence of increased
cellular infiltration or thickening of the dermis (Figure 1a,
upper panel). In contrast, increased cellular infiltration and
dermal thickening are seen in ears and skin of mice when
B10.D2 BM and spleen cells are transplanted (Scl GVHD).
During this early stage we find essentially normal epidermis
in Scl GVHD mice, where apoptotic keratinocytes can rarely
be found (Figure 1b, lower panel). This is in contrast to Cyt
GVHD, which results when C57BL/6 BM and spleen are
transplanted to Balb/c mice. The diagnostic feature of Cyt
GVHD is the formation of many apoptotic keratinocytes
(white arrows, Figure 1b, lower panel) in epidermis and hair
follicles (‘‘epithelial injury out of proportion to the inflamma-
tion’’) (Gilliam et al., 1996; Yoo et al., 1997). Examination of
gut histology of Scl GVHD also showed no GVHD-induced
apoptosis (data not shown). This is consistent with absence of
diarrhea in Scl GVHD mice.
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Figure 1. Skin thickening and not keratinocyte apoptosis is characteristic of
Scl GVHD. Tissue was harvested from either (a) ear or (b) skin and examined
after hematoxylin and eosin staining of paraffin-embedded tissue.
Representative histology of one mouse in each group of three to five mice is
shown. Both cellular infiltration and skin thickening (black arrows), but no
epithelial injury is evident 21 days post-BMT in Scl GVHD mice.
Inflammation and skin thickening are not seen in normal (NOR) or
control BMT mice. There is no skin thickening in mice with Cyt GVHD
(C57BL/6-Balb/c) but cellular infiltration and epithelial injury (white arrows
identify apoptotic keratinocytes) occurs. Black bar represents 100 mm.
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Activated CD4 T cells predominate in early Scl GVHD in both
spleen and skin, but APC activation depends on tissue site
To ensure the development of GVHD in our model, we
added spleen cells that contain mature T cells that will
presumably react with recipient APCs, be activated, and
cause GVHD. Therefore, we evaluated activation rather than
proliferation of transplanted T cells, as determined by the
change of expression from CD62LþCD44 (naı¨ve T cells) to
CD62LCD44þ (activated T cells). We used flow cytometry
analysis of single-cell suspensions of spleens and skin from
either normal mice or mice after 7 or 14 days post-BMT in
either control BMT (Balb/c-Balb/c) or experimental Scl
GVHD (B10.D2-Balb/c) groups. Most splenic CD4þ T cells
are naı¨ve (CD44CD62Lþ ) in both normal (unirradiated, not
transplanted) and control BMT mice, but become activated
(CD44þCD62L) in mice developing Scl GVHD by day 7
post-BMT (Figure 2a). Percentage of CD44þCD62L cells in
spleen of normal and control BMT mice is 24 and 37%,
respectively, compared with 60% in Scl GVHD. In data not
presented here, most splenic CD8þ T cells were nonspeci-
fically activated as we found equal percentage of
CD44þCD62L cells in both BMT control mice and mice
with Scl GVHD, suggesting that CD8þ T cell activation is not
dependent on GVHD in this model. The percentage of
activated CD4þ T cells in the spleen decreased over time,
suggesting migration of activated T cells out of spleen,
apoptosis of activated T cells, and/or replacement by newly
synthesized T cells from donor BM cells (data not shown).
When we calculated exact number of naı¨ve or activated
CD4þ T cells in the spleen, as expected we found more T
cells in the normal mice compared with control or Scl
GVHD mice, but the ratio of naı¨ve to activated was similar in
normal and control group (2:1 in normal and 3:1 in control,
Figure 2b). There was a tremendous skewing in the number
of naı¨ve CD4þ T cells compared with activated during
Scl GVHD (1:7 ratio of naı¨ve to activated T cell, Figure 2b).
The numbers of T cells increase over time post-BMT
in both control and Scl GVHD because of the repopulation
of the spleen from T cells generated from the BM. We found
that in mice given BM alone (either Balb/c or B10.D2),
CD4þ T cell numbers do not start to increase until after day
21 post-BMT.
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Figure 2. Activation of T cells in spleen and skin in Scl GVHD. CD4þ T cells were examined by flow cytometry for expression of activation markers 7 days
after BMT. (a) Activated CD4þ T cells were evaluated by using single-cell suspensions pooled from 3–5 mice/group of either spleen or skin stained with
anti-CD4 antibodies in combination with antibodies for activation markers CD44 and CD62L. The percentages of CD4þ T cells that are activated
(CD44hiCD62Lneg) are indicated in the right lower quadrant. Although activated T cells in the spleen are increased in Scl GVHD mice, most cutaneous CD4þ T
cells are activated in all three groups. (b) Absolute numbers (#) of naı¨ve (CD44CD62Lþ ) or activated (CD44þCD62L) in spleen or skin of normal, control
BMT mice, or Scl GVHD mice were determined by flow cytometric analysis of single-cell suspensions.
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In single-cell suspensions from skin, all CD4þ T cells were
CD44hiCD62Lneg whether isolated from normal (83%),
control BMT (80%), or Scl GVHD (83%) mice (Figure 2a)
suggesting that only activated T cells are found in the
cutaneous environment. This would be expected, as CD62Lþ
naı¨ve cells would not migrate through peripheral tissue.
When we examined absolute number of CD4þ T cells
isolated from skin, we found that both normal and control
mice showed equivalent numbers of naı¨ve and activated T
cells (Figure 2b), whereas Scl GVHD showed almost twofold
increase in both naı¨ve and activated T cells. Despite the
differences in cell number, the ratio of naı¨ve to activated
CD4þ T cells was consistent (1:21 for normal, 1:16 for
control BMT, and 1:17 for Scl GVHD).
To examine APC activation in the spleen and skin, we
focused on the B7 family of costimulatory molecules (CD86
and PDL1/B7H1) because of their essential role in initiating
and regulating T-cell response (Rothstein and Sayegh, 2003).
In control BMT mouse spleen at day 7 post-BMT, only
CD11cþ DCs constitutively expressed CD86 (specific mean
fluorescent value¼64), which is an essential protein in
activating T cells. Splenic CD11cþ DCs from Scl GVHD
mice (thick-line plot), compared with control BMT (thin-line
plot) showed activation as determined by increased expres-
sion of CD86 and PDL1/B7-H1 (Figure 3, upper panel). The
numbers in regular and bold font show the specific mean
fluorescent value for control BMT and Scl GVHD, respec-
tively. For splenic CD11cþ DCs, the specific mean fluor-
escent value increases from 64 to 90 for CD86 expression and
from 60 to 99 for PDL1. This activation is diminished by 21
days post-BMT (data not shown). Splenic CD11bþ macro-
phages expressed very low levels of CD86 and PDL1/B7-H1,
which were not influenced by Scl GVHD, as there is little
difference for control BMT and Scl GVHD (Figure 3, upper
panel). In skin, both CD11bþ macrophages and CD11cþ
DCs constitutively express CD86 and PDL1/B7-H1. They also
show increased expression of CD86 and PDL1/B7-H1 during
Scl GVHD, shown by the shift in specific mean fluorescent
value in Scl GVHD compared with control BMT (Figure 3,
lower panel). This suggests that unlike in spleen, cutaneous
CD11bþ macrophages and CD11cþ DCs are being acti-
vated. In addition, cutaneous APCs would not be signaling to
the T cells predominately through CD28 (ligand for CD86),
but may be using PD-1 (ligand for PDL1) instead. This
interaction is known to promote T-cell apoptosis and IL-10
production (Dong et al., 1999, 2002). This is an important
observation suggesting that cutaneous APCs would not be
supportive of T-cell proliferation or cytokine production.
Cutaneous APCs fail to support activated CD4þ T cells in vitro
in the Scl GVHD model, but not the Cyt GVHD model
To evaluate the ability of cutaneous APCs to support the
ability of activated CD4þ T cells that would be entering the
skin during Scl GVHD, we tested cutaneous CD11bþ
macrophages and CD11cþ DCs for their ability to support
the proliferation of B10.D2 CD4þ T cells that had previously
been activated by splenic CD11cþ DCs. To determine if the
APC–T cell interaction was dependent on APC population or
population of CD4þ T cell encountered, we also examined
the ability of cutaneous CD11bþ and CD11cþ cells in
supporting proliferation of C57BL/6 CD4þ T cells, a
population of T cells that can generate Cyt GVHD. Although
CD11bþ macrophages and CD11cþ DCs were not suppor-
tive of B10.D2 CD4þ T-cell proliferation (Figure 4a), both
populations of cutaneous APCs were supportive of C57BL/6
CD4þ T cell proliferation (Figure 4b).
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Figure 3. Activation of APCs in spleen and skin in Scl GVHD. Purified CD11cþ DCs and CD11bþ macrophages from spleen or skin were stained with
either anti-CD86 or -PDL1 antibodies and examined by flow cytometry for costimulatory molecules that would be important in T-cell activation. In the spleen,
only CD11cþ DCs were activated based on increased expression of CD86 and PDL1, whereas in the skin, both CD11cþ and CD11bþ cells showed increased
expression of PDL1, an inhibitory rather than stimulatory molecule. Numbers in normal font represent specific mean fluorescent value of control BMT,
whereas numbers in bold font represent specific mean fluorescent value from Scl GVHD (Isotype control Ab – gray-filled plot; control BMT – thin-lined plot; Scl
GVHD – thick-lined plot). Tissues from 3 to 5 animals were pooled together for analysis. The results are representative of four separate experiments.
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What is the T-cell cytokine profile in spleen and skin in early
Scl GVHD?
We examined the ability of CD4þ T cells from spleen and
skin to synthesize cytokines in short-term culture. Numbers of
CD4þ T cells synthesizing IFNg, IL-2, and TNFa were
evaluated by flow cytometric analysis (Figure 5). Splenic
CD4þ T cells from mice developing Scl GVHD producing
IFNg, IL-2, and TNFa are increased by day 7 post-BMT (thick-
line plot, Figure 5, upper panels) compared with control BMT
mice (thin-line plot). This production of cytokines in the
spleen decreased over time with few cells producing
cytokines by day 14 and day 21 post-BMT, correlating with
decrease in activated T cells in the spleen over time (Figure 5,
middle panels; day 21 not shown). Activated cutaneous
CD4þ T cells are found in the skin of all mice, but only
CD4þ T cells isolated from skin of mice with Scl GVHD
produced IFNg and IL-2 (Figure 5b). Unlike their splenic
counterparts, few cutaneous CD4þ T cells produced TNFa.
The data for skin cytokine-producing cells are presented in
the chart at the bottom of Figure 5.
We used gene array analysis of total skin mRNA from
normal mice, control BMT mice, and Scl GVHD mice to
evaluate the cutaneous cytokine mRNA environment in early
Scl GVHD (day 30). We found that skin from Scl GVHD mice
had increased mRNA expression for the following cytokines:
IFNg, IL-2, IL-10, IL-18, and TGFb1 (Figure 6). No IFNg or IL-
2 mRNA expression was seen in control BMT mice, and we
found lower levels of IL-10, IL-18 and TGFb1 in control BMT
mice compared with Scl GVHD mice. IL-10 mRNA expres-
sion in the skin of mice undergoing Scl GVHD is increased
compared with control BMT (156 vs 30, fivefold increase).
We failed to identify any IL-10-producing CD4þ T cells by
flow cytometry (data not shown), suggesting that other cells
such as macrophages may be expressing IL-10 mRNA. IL-18
was increased in Scl GVHD compared with control BMT
mice (1,819 vs 574, threefold increase). One major function
of IL-18 is to enhance IFNg production (Nakanishi et al.,
2001; Tsutsui et al., 2004). IL-18 may help to maintain a
strong Th1-like environment. The fold increase in TGFb1 (Scl
GVHD – 408 vs control BMT – 83, fivefold increase) is
consistent with our previously reported results by semiquan-
titative RT-PCR (Zhang et al., 2002a). In either Scl GVHD or
control BMT groups, there was no expression of IL-4, IL-5, or
TNFa (Figure 6). The cytokine environment (IFNg, IL-2, IL-18
high, no IL-4, or IL-5) suggests infiltration by Th1-like T cells
in early fibrosing disease. In addition, mRNA for TNFa, a
cytokine critical to epithelial cell injury, is not present in the
skin of mice undergoing Scl GVHD. These data have been
confirmed by RT-PCR analysis and are reported separately
(Zhou et al., 2007).
DISCUSSION
Pathophysiology of Scl GVHD
The mechanism for GVHD initiation is dependent on the
model studied. Cyt GVHD is characterized by epithelial
injury and is mediated by CD4þ and CD8þ T cells and
natural killer cells, with cytokines such as TNFa and IFNg
critical for disease (Shustov et al., 1998; Kataoka et al., 2001;
Ichiki et al., 2006). For instance, C57BL/6 donor (H-2b) cells
transplanted into lethally irradiated Balb/c mice (H-2d) will
produce Cyt GVHD as shown in Figure 1. In Scl GVHD,
CD4þ T cells and macrophages are the major cells involved
(McCormick et al., 1999; Zhang et al., 2002a, 2003; Kaplan
et al., 2004; Anderson et al., 2005). Figure 1 also shows that
B10.D2 donor (H-2d) cells produce Scl GVHD in the same
recipient mouse strain used to generate Cyt GVHD using
C57BL/6 donors (McCormick et al., 1999; Zhang et al.,
2002a; Zhang et al., 2003). Although the C57BL/6-Balb/c
mismatch is across major histocompatability loci, transplant-
ation across minor histocompatability loci can also produce
Cyt GVHD. Others have shown that using congenic mice that
differed at major histocompatibility complex loci it is possible
to generate either cytotoxic or Scl GVHD (Kaplan et al.,
2004). Therefore the form of GVHD may be dependent on
the target antigens selected by the different major histocom-
patibility complex molecules based on binding affinity of
peptides to the major histocompatibility complex molecules.
The combination of different peptides and different major
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Figure 4. Capacity of cutaneous APCs to function as stimulators of activated
CD4þ T cells in mixed leukocyte reactions depends on specific T-cell
population. Cutaneous APCs were examined for their ability to restimulate
activated CD4þ T cells from either (a) B10.D2 or (b) C57Bl/6 mice. Although
neither CD11bþ nor CD11cþ cutaneous APCs were capable of restimulating
activated B10.D2 CD4þ T cells, both populations could restimulate C57Bl/6
CD4þ T cells. Values identified by * were found to be significantly different
(Po0.01) from media-alone controls. Results are representative of three
separate experiments.
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histocompatibility complex molecules will allow selection
for different T-cell repertoires that may account for the GVHD
phenotype (Kaplan et al., 2004).
Where and how is GVHD initiated?
Splenic DCs are sufficient to induce GVHD by activating
donor T cells that are different at major histocompatibility
complex or minor histocompatability complex loci (Duffner
et al., 2004). In a study to examine the role of resident APCs
in promoting infiltration of GVHD-causing T cells into
different tissues, mice that had splenic and hepatic APCs
depleted by liposomes were injected with splenic T cells
isolated from mice undergoing Cyt GVHD (Zhang et al.,
2002b). Although these mice showed no evidence of GVHD
in the spleen or liver, they developed cutaneous GVHD,
suggesting that activation of T cells in the spleen results in
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Figure 5. Splenic and cutaneous CD4þ T cells differ at production of TNFa in Scl GVHD. (a) Splenic CD4þ T cells isolated 7 days after BMT from Scl
GVHD mice (thick-line plot) showed increased number of IFNg-, IL-2-, and TNFa-producing CD4þ T cells compared with control BMT mice (thin-line plot) and
isotype control (gray-filled plot). The percentage of CD4þ T cells producing cytokines decreased by day 14 post-BMT. (b) Scl GVHD mice showed increased
cutaneous CD4þ T cells expressing IFNg and IL-2, but not TNFa-positive cells compared with control BMT mice 7 days after BMT. We also found fewer
IFNg- and IL-2-producing CD4þ T cells 14 days post-BMT. Tissues from five animals were pooled together for analysis. The results are representative of three
separate experiments.
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generation of GVHD-causing skin-homing T cells. Expression
of CD80/CD86 by splenic APCs is important in inducing
cutaneous GVHD (Anderson et al., 2005). In our studies, we
found that only splenic CD11cþ DCs constitutively express
CD86, suggesting that they are capable of initiating GVHD by
activating T cells. In addition, splenic CD11cþ DCs also
show upregulation of CD86 and PDL1 during the early stage
of Scl GVHD. We demonstrated activation of splenic CD4þ
T cells in Scl GVHD that had increased numbers of
CD44hiCD62Lneg cells that produce IFNg, IL-2, and TNFa,
similar to what would be expected in the cytokine profile of
Cyt GVHD (Ichiki et al., 2006). In human scleroderma, both
Th1- and Th2-like cytokines have been reported (Mavalia
et al., 1997; Valentini et al., 2001; Abraham and Varga,
2005; Rottoli et al., 2005). A caveat to these data on
scleroderma patients is that when human scleroderma is
diagnosed, it is often well established, so correlating cytokine
production with triggers of disease may not be possible.
APC–T cell interactions in skin in Scl GVHD
APCs in the periphery (lymph node and spleen) are essential
for activation of donor T cells in GVHD. On entry into the
skin, these T cells will then encounter different populations of
resident APCs. Cutaneous APCs have been shown to be
essential for the development of Cyt GVHD, as replacement
of recipient Langerhans cells (LC) with donor LC by low-dose
T cell administration protected the recipient from developing
GVHD on rechallenge with a large dose of T cells (Merad
et al., 2004). Neither cutaneous CD11cþ DCs nor CD11bþ
macrophages freshly isolated from skin were capable of
supporting proliferation of activated B10.D2 CD4þ T cells,
but they could support proliferation of activated C57BL/6
CD4þ T cells. These data suggest that cutaneous APCs would
not be supportive of T-cell proliferation in Scl GVHD.
The difference between normal function and pathology is
often a fine balance between regulation of opposing factors.
Although IFNg and TNFa are thought to inhibit wound
healing through their ability to suppress TGFb signaling (Mori
et al., 2002; Ishida et al., 2004), TGFb can also inhibit IFNg
synthesis (Yu et al., 2006). As we find mRNA for IFNg and
TGFb but no TNFa in skin, the absence of TNFa may be, in
part, responsible for pathology of Scl GVHD. Although we
find some CD4þ T cells that are capable of producing TNFa
ex vivo on restimulation with anti-CD3, there were fewer
than those found in control BMT (Figure 5). Our gene array
data suggest that TNFa is not induced in skin during Scl
GVHD at any time; these results reflect TNFa mRNA from
both T cells and macrophages. Thus, TNFa, which has been
shown to be essential for Cyt GVHD (Korngold et al., 2003;
Schmaltz et al., 2003), is absent in the skin during Scl GVHD.
Therefore, we have identified three possible factors in the
development of fibrosis rather than epithelial injury in Scl
GVHD. First, cutaneous APCs, through their expression of the
inhibitory molecule PDL1, do not support T-cell activation
and no cytotoxic CD4þ or CD8þ T cells are generated.
Second, the absence of TNFa-producing CD4þ cutaneous T
cells and TNFa mRNA in skin by gene array analysis during
early Scl GVHD may be a key factor because TNFa induces
keratinocyte apoptosis, leading to epithelial injury that is
characteristic of Cyt GVHD. Third, TNFa is also a potent
inhibitor of TGFb-induced fibrosis (Yamane et al., 2003;
Schiller et al., 2004). In some patients with Cyt GVHD, as
TNFa levels in the serum increase, TGFb levels decrease,
suggesting a regulatory balance between these two cytokines
(Remberger et al., 2003; Visentainer et al., 2003). There is
some evidence that TGFb production by T cells is important
in regulating acute GVHD (Banovic et al., 2005). In our
model, we find splenic CD4þ T cells that are capable of
producing TNFa, but they are not found in skin. TNFa is
elevated in the blood of patients with scleroderma compared
with controls (Young et al., 2002; Scala et al., 2004), and
activated peripheral blood mononuclear cell from these
individuals also produce increased amounts of TNFa
compared with controls (Scala et al., 2004). However, these
cells have not been demonstrated in the skin.
Implications for therapy in scleroderma
Our data suggest that the absence of TNFa production in skin
may have profound effects on the development of Scl GVHD
in its early stages. If the lack of TNFa promotes fibrosis, can
TNFa induction be therapeutic for scleroderma and Scl
GVHD? Th2-like CD4þ T cells can inhibit collagen synthesis
by dermal fibroblasts in vitro through the actions of
membrane-bound TNFa (Chizzolini et al., 2003). Thalido-
mide has been used in the treatment of scleroderma patients
with some success (Browne et al., 2000; Oliver et al., 2000).
Despite the ability of thalidomide to inhibit TNFa production
by monocytes, this treatment result in the increase of serum
levels of TNFa. This increase in serum TNFa would be due to
increased production by other cell types including T cells.
Therefore, selective targeting of skin to increase TNFa
production may have some benefit in Scl GVHD.
2,000
Scl GVHD
CON BMT1,800
1,600
1,400
1,200
1,000
Fo
ld
 in
cr
ea
se
 in
 m
RN
A 
ex
pr
es
sio
n
800
600
400
200
0
IFN TNF TGF1IL4 IL5 IL10 IL18IL2
* * *
Figure 6. Induction of mRNAs for cytokine genes in Scl GVHD mice. Skins
from normal mice, control BMT mice (Balb/c-Balb/c), and Scl GVHD mice
(B10.D2-Balb/c) were isolated and RNA was extracted from whole tissue at
day 30. Gene expression in Scl GVHD mice (closed bar) and control BMT
mice (open bar) were compared with mRNA in normal mice. There was no
detectable mRNA for TNFa, IL-4, or IL-5 in skin in either Scl GVHD mice or
control BMT mice as indicated by * in the graph. The results are representative
of three separate experiments.
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A cautionary note in dealing with immunological dis-
orders with complex interdependent pathways is that by
inhibiting Scl GVHD, one may promote the development of
Cyt GVHD. Continued testing of potential agents for
scleroderma in mouse models is therefore critical to
development of more effective therapies.
MATERIALS AND METHODS
BMT to generate Scl GVHD or Cyt GVHD
In a typical transplantation experiment, 5- to 8-week-old male and
female B10.D2 (H-2d) and Balb/c (H-2d) mice (Jackson Laboratories,
Bar Harbor, ME) are used as donors and recipients, respectively, for
BMT to produce Scl GVHD (McCormick et al., 1999; Zhang et al.,
2002a, 2003). C57BL/6 (H-2b) and Balb/c (H-2d) mice (Jackson
laboratories) are used as donors and recipients, respectively, to
generate Cyt GVHD. Briefly, female recipient mice are lethally
irradiated with 700 cGy from a Gammacel 137Cs source (J.L.
Shepard and Associates, San Fernando, CA). Mice are injected with
male donor-BM cells (1.5 106/mouse) and spleen cells (3 106/
mouse) suspended in RPMI-1640 (BioWhittaker, Walkersville, MD)
with 20 U/ml heparin (Fisher Scientific, Pittsburgh, PA). A control
group of female Balb/c mice receive male Balb/c BM and T cells
(syngeneic BMT). We have used male donor cells and female
recipient mice to track donor leukocytes in previous experiments
(McCormick et al., 1999; Zhang et al., 2002a, 2003). Animals that
do not engraft die within 10–14 days. Three to five animals are
studied at each time point. Case Western Reserve University School
of Medicine’s Institutional Animal Care and Use Committee have
approved all studies involving animals.
Tissue collection and RNA extraction, preparation, and
characterization
At least three animals per group (experimental Scl GVHD and
control BMT) per time point were killed via cervical dislocation 7,
14, 21, or 30 days post-BMT in six separate experiments. Back skin
was chemically depilated and harvested for buffered formalin
fixation (Surgipath Medical Industries, Richmond, IL), paraffin
embedding (Sakura Finetech, Torrance, CA), routine histology for
hematoxylin and eosin staining and for measurement of skin
thickness (McCormick et al., 1999; Zhang et al., 2002a, 2003). Skin
was also collected for flow cytometric analysis and for RNA
extraction (snap-frozen in liquid nitrogen and stored at 801C).
Total RNA was isolated using TRIzol reagent as per manufacturer’s
protocol (GibcoBRL, Carlsbad, CA). RNA quality was assessed by
spectrophotometer at 260/280 nm absorption and the integrity and
overall quality was evaluated by native agarose gel electrophoresis.
Biotinylated riboprobes synthesized from total RNA specimens were
initially hybridized to an Affymetrix Test3 miniarray (Affymetrix,
Santa Clara, CA) to verify probe quality.
Gene expression analysis
Gene expression was interrogated using Affimetrix Mouse Genome
Arrays 430A, which contain 22,600 oligonucleotide probe sets for
approximately 14,000 well-characterized genes. Total skin RNA was
used to prepare biotinylated target cRNA, with minor modifications
from the manufacturer’s recommendations. The target biotinylated
cRNA was processed as per manufacturer’s recommendation using
an Affymetrix GeneChip instrument system. Arrays were then
washed and stained with steptavidin–phycoerythrin before being
scanned on an Affymetrix GeneChip scanner. The fluorescent
intensity of each probe was quantified using Microarray Analysis
Suite version 5.0 (Affymetrix). Additional annotation data was
incorporated into the data set using the Affymetrix web-based
analysis tool NetAffx. The signals displayed for the genes in each
sample that were included in the trimmed data set were imported
into GeneSpring software version 7.2 (Silicon Genetics, San Carlos,
CA). To present the relative expression for a given gene or probe set
in each sample, the measured signal for each probe set was
normalized to sample 1, which was from normal female Balb/c
mouse skin. One-way hierarchical clustering with Pearson correla-
tion analyses and minimum distance of 0.001 was employed to order
genes in the trimmed data set for the time course of the two groups.
Details of gene array analysis on murine Scl GVHD are published
separately (Zhou et al., 2007).
Preparation of single-cell suspensions
Spleen was minced into small pieces and digested in RPMI-5% fetal
bovine serum (Hyclone, Logan, UT) containing 300 U/ml collage-
nase type 3 (Worthington Biochemical, Lakewood, NJ) and 30 U/ml
DNase I (Sigma-Aldrich, St Louis, MO) at 371C for 1 hour. Depilated
skin was digested in RPMI-5% fetal bovine serum containing
500 U/ml Collagenase type 3, 30 U/ml DNase I and 1000 U/ml
Hyaluronidase (Worthington) at 371C for 1 hour. Cells were then
passed through a 70-mm cell strainer Falcon (Bectin Dickenson
Labware, Franklin Lakes, NJ) to generate single-cell suspensions.
Dead cells and cellular debris were removed from the single-cell
suspensions by placing cell suspensions on a discontinuous gradient
with Ficoll-Paque (Pharmacia, Uppsala, Sweden).
Flow cytometry of single-cell suspensions
Antibodies and appropriate isotype controls (eBioscience, San
Diego, CA or BD Pharmingen, San Diego, CA) were used as follows:
anti-CD4 (clone RM4-5), anti-CD11b (clone M1/70), anti-CD11c
(clone N418), anti-CD44 (clone IM7), anti-CD62L (clone MEL-14),
anti-CD86 (clone GL1), anti-PDL1/B7-H1 (MIH5:), anti-IFNg (clone
XMG1.2), anti-IL-2 (clone JES6-5H4), and anti-TNFa (clone MP6-
XT22). Isolated cells were incubated for 20 minutes at 41C in
blocking buffer which contained 10% normal mouse serum in FACS
buffer (0.1% bovine serum albumin in phosphate-buffered saline).
Cells were washed twice in FACS buffer and fixed using Cytofix/
perm solution (BD Pharmingen). For intracellular cytokine staining,
single-cell suspensions from spleen or skin were incubated on anti-
CD3-coated plates for 5–6 hours in RPMI-5% fetal bovine serum
containing 1mg/ml brefeldin A (Golgiplug, BD Pharmingen). Cells
were then incubated with blocking buffer for 20 minutes at 41C,
followed by incubation with anti-CD4 for an additional 20 minutes.
Cells were then fixed with paraformaldehyde, washed in the
presence of saponin (Perm/Wash buffer, BD Pharmingen), incubated
with fluorescent anti-cytokine antibodies, washed, and examined on
a LSR I flow cytometer (BD Bioscience). All data were analyzed
using FlowJo analysis software (Tree Star Inc., Ashland, OR).
Purification of APCs and T cells by magnetic bead isolation
CD11cþ DCs and CD11bþ macrophages were isolated from Balb/c
spleen and skin with anti-CD11cþ - and anti-CD11bþ -coated
magnetic beads using positive selection (Miltenyi Biotec Inc.,
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Auburn, CA). Single-cell suspensions from tissue were incubated first
with anti-CD11cþ -coated microbeads and then separated on
magnetic columns. The flow through, which comprised CD11c
cells, was then incubated with anti-CD11bþ -coated microbeads and
isolated on magnetic columns. By this method we were able to
separate CD11bþ DCs from CD11bþ macrophages. CD4þ T cells
were enriched from B10.D2 mouse tissue by negative selection using
CD4 T cell isolation kits respectively (Miltenyi Biotec Inc.).
Approximately 1 105 CD11cþ DCs and 5 105 CD11bþ macro-
phages could be isolated from 0.5 g of skin. Purity of cells was
determined by flow cytometry for each population (480%).
Mixed leukocyte cultures
Cultures were established using CD11bþ macrophages or CD11cþ
DCs isolated from either skin or spleen of Balb/c mice as stimulatory
APCs and responding CD4þ T cells isolated from spleen of B10.D2
mice. For primary proliferation cultures, APCs were added at
different concentrations in the presence of 2 105 CD4þ T cells
in 96-well plates (Falcon). Cultures were incubated at 371C for 4
days. For secondary proliferation CD4þ T cells were first cultured
with CD11cþ splenic DCs for 4 days. CD4þ T cells were purified
from cultures through negative selection using CD11cþ microbeads.
CD4þ T cells were then cultured for an additional 4 days in the
presence of media alone, CD11cþ splenic DCs, CD11cþ cutaneous
DCs, or CD11bþ cutaneous macrophages. For proliferation studies,
1.0 mCi of 3H-thymidine (Perkin Elmer Life Science, Boston, MA) was
added to the culture for the last 8 hours. Cells were then harvested
and the amount of 3H-thymidine incorporated into T cells was
measured. For ELISA studies, supernatant was collected from primary
and secondary cultures at specific time points and frozen at 801C.
Supernatant was then analyzed using Quantikine kit for TGFb (R&D
systems, Minneapolis, MN). For ELISA experiments, RPMI containing
5% normal mouse serum (Jackson ImmunoResearch, West Grove,
PA) was used in place of RPMI-5% fetal bovine serum.
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